1. Unified classification and risk-stratification in Acute Myeloid Leukemia
- Author
-
Yanis Tazi, Juan E. Arango-Ossa, Yangyu Zhou, Elsa Bernard, Ian Thomas, Amanda Gilkes, Sylvie Freeman, Yoann Pradat, Sean J. Johnson, Robert Hills, Richard Dillon, Max F. Levine, Daniel Leongamornlert, Adam Butler, Arnold Ganser, Lars Bullinger, Konstanze Döhner, Oliver Ottmann, Richard Adams, Hartmut Döhner, Peter J. Campbell, Alan K. Burnett, Michael Dennis, Nigel H. Russell, Sean M. Devlin, Brian J. P. Huntly, Elli Papaemmanuil, Tazi, Yanis [0000-0002-1595-9631], Bernard, Elsa [0000-0002-2057-7187], Freeman, Sylvie [0000-0003-1869-180X], Pradat, Yoann [0000-0002-4647-5779], Dillon, Richard [0000-0001-9333-5296], Levine, Max F [0000-0001-5156-9086], Leongamornlert, Daniel [0000-0002-3486-3168], Döhner, Konstanze [0000-0002-2261-9862], Adams, Richard [0000-0003-3915-7243], Döhner, Hartmut [0000-0003-2116-5536], Campbell, Peter J [0000-0002-3921-0510], Burnett, Alan K [0000-0003-1734-5817], Devlin, Sean M [0000-0002-6801-720X], Huntly, Brian JP [0000-0003-0312-161X], Papaemmanuil, Elli [0000-0003-1709-8983], and Apollo - University of Cambridge Repository
- Subjects
Cancer Research ,Multidisciplinary ,Neoplasm, Residual ,article ,General Physics and Astronomy ,General Chemistry ,631/67/69 ,Induction Chemotherapy ,Flow Cytometry ,General Biochemistry, Genetics and Molecular Biology ,Leukemia, Myeloid, Acute ,Cytogenetic Analysis ,Humans ,692/4028/67/1990/283/1897 ,631/208/69 - Abstract
Funder: E.P. is a Josie Robertson Investigator and is supported by the European Hematology Association, American Society of Hematology, Gabrielle’s Angels Foundation, V Foundation and The Geoffrey Beene Foundation and is a Damon Runyon Rachleff Innovator fellow. Work in the BJPH lab is funded by Cancer Research UK (C18680/A25508), the European Research Council (647685), MRC (MR-R009708-1), the Kay Kendall Leukaemia Fund (KKL1243), the Wellcome Trust (205254/Z/16/Z) and the Cancer Research UK Cambridge Major Centre (C49940/A25117). This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014), and was funded in part, by the Wellcome Trust who supported the Wellcome - MRC Cambridge Stem Cell Institute (203151/Z/16/Z). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. L.B., H.D. and B.J.P.H. are supported by the HARMONY Alliance (IMI Project No. 116026; https://www.harmony-alliance.eu/). The UK-NCRI AML working group trials were supported with research grants from the Medical Research Council (MRC), Cancer Research UK (CRUK), Blood Cancer UK and Cardiff University. We would like to thank all patients and investigators for their participation in the trials and the study., Clinical recommendations for Acute Myeloid Leukemia (AML) classification and risk-stratification remain heavily reliant on cytogenetic findings at diagnosis, which are present in
- Published
- 2022